Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adoptive immunotherapy (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal, Intratumoral, Intravenous, Parenteral
01
Overview
This is an autologous adoptive cellular immunotherapy developed by the Chinese PLA General Hospital for the treatment of hepatocellular carcinoma (HCC), often used in combination with microwave ablation (MWA). The therapy involves the ex vivo expansion and activation of multiple immune cell types from the patient's own peripheral blood, including cytokine-induced killer (CIK) cells, dendritic cell-cytokine-induced killer (DC-CIK) cells, and cytotoxic T lymphocytes (CTLs). The treatment protocol is complex, involving intravenous infusion of CIK cells, intraperitoneal injection of DC-CIK and CTLs, and intralesional/intranodal injection of dendritic cells. This multi-pronged approach aims to enhance the systemic anti-tumor immune response, eradicate residual micro-metastases, and prevent recurrence in HCC patients.
- Other names
- expanding activated autologous lymphocytesCIK + DC-CIK + CTL therapyautologous immune cell therapy
02
Targets
Beyond the preview
Go deeper on adoptive immunotherapy (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adoptive immunotherapy (Chinese PLA General Hospital).